HK1202418A1 - 用於生物活性試劑的緩釋的藥物遞送系統 - Google Patents

用於生物活性試劑的緩釋的藥物遞送系統

Info

Publication number
HK1202418A1
HK1202418A1 HK15102889.3A HK15102889A HK1202418A1 HK 1202418 A1 HK1202418 A1 HK 1202418A1 HK 15102889 A HK15102889 A HK 15102889A HK 1202418 A1 HK1202418 A1 HK 1202418A1
Authority
HK
Hong Kong
Prior art keywords
bioactive agents
sustained
delivery system
drug delivery
delivery
Prior art date
Application number
HK15102889.3A
Other languages
English (en)
Inventor
Antti Laukkanen
Ruzica Kolakovic
Leena Peltonen
Timo Laaksonen
Jouni Hirvonen
Heikki Lyytikinen
Harri Jukarainen
Prijo Kortesuo
Original Assignee
Upm Kymmene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upm Kymmene Corp filed Critical Upm Kymmene Corp
Publication of HK1202418A1 publication Critical patent/HK1202418A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK15102889.3A 2011-11-15 2015-03-23 用於生物活性試劑的緩釋的藥物遞送系統 HK1202418A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20116138A FI130619B (en) 2011-11-15 2011-11-15 Matrix for controlled release of bioactive substances
PCT/FI2012/051121 WO2013072563A1 (en) 2011-11-15 2012-11-15 Drug delivery system for sustained delivery of bioactive agents

Publications (1)

Publication Number Publication Date
HK1202418A1 true HK1202418A1 (zh) 2015-10-02

Family

ID=47351708

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102889.3A HK1202418A1 (zh) 2011-11-15 2015-03-23 用於生物活性試劑的緩釋的藥物遞送系統

Country Status (6)

Country Link
US (1) US11389537B2 (zh)
EP (1) EP2779996B1 (zh)
JP (1) JP6178329B2 (zh)
FI (1) FI130619B (zh)
HK (1) HK1202418A1 (zh)
WO (1) WO2013072563A1 (zh)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI125942B (en) 2013-07-26 2016-04-15 Upm Kymmene Corp A method of modifying a nanofibril cellulose composition
FI125882B (en) 2014-12-22 2016-03-31 Upm Kymmene Corp Heat treatment of a hydrogel of nanofibrillar cellulose
FI125883B (en) 2014-12-22 2016-03-31 Upm Kymmene Corp Treatment of Catalytically Oxidized Nanofibril Cellulose Hydrogel
FI126120B (en) * 2014-12-22 2016-06-30 Upm Kymmene Corp Process for preparation of oxidized hydrogel of nanofibrillar cellulose
FI127834B (en) * 2015-06-04 2019-03-29 Upm Kymmene Corp Process for the production of nanofibril cellulose hydrogel
US11173130B2 (en) * 2015-09-24 2021-11-16 Massachusetts Eye And Ear Infirmary Drug delivery system and methods of use
US20190008804A1 (en) * 2016-01-12 2019-01-10 Repros Therapeutics Inc. Trans-Clomiphene and Progesterone Receptor Antagonist Combination Therapy for Treating Hormone-Dependent Conditions
WO2018009139A1 (en) * 2016-07-08 2018-01-11 Cellutech Ab A cellular solid material drug carrier comprising cellulose nanofibers (cnf) wherein the cellular solid material comprises closed cells
KR102348203B1 (ko) * 2016-08-08 2022-01-10 닛뽕세이시 가부시키가이샤 셀룰로스 나노섬유 수분산액, 및 셀룰로스 나노섬유를 함유하는 식품, 화장품 및 고무 조성물
EP3335695B1 (en) 2016-12-15 2020-02-05 UPM-Kymmene Corporation A method for freeze-drying hydrogel comprising nanofibrillar cellulose, a freeze-dried medical hydrogel comprising nanofibrillar cellulose, and a hydrogel comprising nanofibrillar cellulose
DK3335696T3 (da) * 2016-12-15 2020-03-16 Upm Kymmene Corp Fremgangsmåde til tørring af cellefrit vævsekstrakt i en hydrogel omfattende nanofibrillær cellulose og en tørret hydrogel omfattende nanofibrillær cellulose og cellefrit vævsekstrakt
WO2019108887A1 (en) * 2017-11-30 2019-06-06 Warner Babcok Institute For Green Chemistry, Llc Products comprising plant-based micro fibers
KR102200787B1 (ko) * 2017-12-29 2021-01-12 한경대학교 산학협력단 나노셀룰로오스를 이용한 습윤성 탄력붕대
EP3616730A1 (en) 2018-08-28 2020-03-04 UPM-Kymmene Corporation Composition or matrix for storage of bacteriophages comprising nanofibrillar cellulose
JP7147490B2 (ja) * 2018-11-07 2022-10-05 凸版印刷株式会社 徐放性複合粒子、徐放性複合粒子の製造方法及び乾燥粉体
HUP1900226A1 (hu) * 2019-06-21 2020-12-28 Hummel Zoltan Dr Hidrofil mikrobiális cellulóz nanorostokat tartalmazó hordozóanyag (gél) a bélnyálkahártya állapotának javítására
EP3791864A1 (en) 2019-09-13 2021-03-17 UPM-Kymmene Corporation Method for preparing pharmaceutical composition and pharmaceutical composition
EP3791858A1 (en) * 2019-09-13 2021-03-17 UPM-Kymmene Corporation Injectable pharmaceutical formulation
BR102020007749A2 (pt) * 2020-04-17 2021-11-03 Edson Luiz Peracchi Implante subcutâneo reabsorvível de longa duração com liberação controlada de substância farmacologicamente ativa pré-concentrada em polímero para tratamento da endometriose
WO2022118104A1 (en) 2020-12-01 2022-06-09 3M Innovative Properties Company Article for storage of bacteriophages and method thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04243819A (ja) 1991-01-25 1992-08-31 Grelan Pharmaceut Co Ltd 徐放性製剤
US5405953A (en) * 1993-08-03 1995-04-11 Biocontrol Incorporated Microfibrillated oxycellulose
JP4308336B2 (ja) * 1997-03-14 2009-08-05 株式会社日本吸収体技術研究所 ミクロフィブリル状微細繊維構造体およびその製造方法
AU2001283107A1 (en) * 2000-09-14 2002-03-26 University Of Iowa Research Foundation Powdered/microfibrillated cellulose
JP2006160627A (ja) * 2004-12-03 2006-06-22 Kyowa Hakko Kogyo Co Ltd 時限放出化方法
JP2006160626A (ja) 2004-12-03 2006-06-22 Kyowa Hakko Kogyo Co Ltd 徐放化方法
US8951551B2 (en) 2005-08-31 2015-02-10 Board Of Regents, The University Of Texas System Multiribbon nanocellulose as a matrix for wound healing
EP2545976B1 (en) * 2006-02-13 2016-08-03 Donaldson Company, Inc. Web comprising fine fiber and reactive, adsorptive or absorptive particulate
CN101172164A (zh) 2006-11-03 2008-05-07 中国科学院化学研究所 可生物降解及吸收的生物高分子纳米纤维膜材料及其制法和用途
CA2710550C (en) 2007-12-28 2015-02-24 Nippon Paper Industries Co., Ltd. Processes for producing cellulose nanofibers, cellulose oxidation catalysts and methods for oxidizing cellulose
US20100159046A1 (en) 2008-12-19 2010-06-24 Xylos Corporation Minimal tissue attachment implantable materials
FI20095638A0 (fi) 2009-06-09 2009-06-09 Valtion Teknillinen Hydrofobiineja aktiivisten aineiden dispergointiin
FI123988B (fi) 2010-10-27 2014-01-31 Upm Kymmene Corp Soluviljelymateriaali
US8758826B2 (en) 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods

Also Published As

Publication number Publication date
EP2779996C0 (en) 2024-04-10
JP2014533296A (ja) 2014-12-11
US20140322327A1 (en) 2014-10-30
FI130619B (en) 2023-12-15
EP2779996A1 (en) 2014-09-24
EP2779996B1 (en) 2024-04-10
JP6178329B2 (ja) 2017-08-09
WO2013072563A1 (en) 2013-05-23
US11389537B2 (en) 2022-07-19
FI20116138L (fi) 2013-05-16

Similar Documents

Publication Publication Date Title
HK1202418A1 (zh) 用於生物活性試劑的緩釋的藥物遞送系統
HK1206634A1 (zh) 用於控制釋放不同藥物成分的媒介物
SG11201401851UA (en) Methods for drug delivery
EP2683431A4 (en) DRUG DELIVERY SYSTEM
HK1205928A1 (zh) 種眼部給藥系統
PL2654864T3 (pl) System dostarczania leku
BR112013018828A2 (pt) sistemas de distribuição de droga
EP2707146A4 (en) NOZZLES FOR NASAL DRUG DELIVERY
EP2771058A4 (en) IMPLANTABLE DEVICES FOR ADMINISTERING BIOACTIVE AGENTS
HK1213480A1 (zh) 用於持續釋放蛋白質的生物可降解的藥物遞送系統
HUE062316T2 (hu) Gyógyszer-adagolási technológia
EP2682075A4 (en) STENT PLACEMENT SYSTEM
EP2776091A4 (en) METHODS FOR DELIVERY OF VISCOUS MEDICINAL TREATMENTS
HRP20181316T1 (hr) Tehnologija isporuke lijeka
EP2689753A4 (en) STENT DELIVERY SYSTEM
ZA201309156B (en) Drug delivery system
IL227352A0 (en) A system for ocular administration of a drug
IL236757B (en) A device for administering a drug with retention in the digestive tract
EP2679202A4 (en) STENT PLACEMENT SYSTEM
EP2717802A4 (en) RECOVERABLE STENT DISPENSING SYSTEM
GB201110632D0 (en) Drug delivery formulations
EP2896401A4 (en) TARGETED ACTIVE AGGREGATION SYSTEM FOR HEAVY-DUTY ACTIVE SUBSTANCE
EP2768488A4 (en) TWO-PHASE PHARMACEUTICAL DELIVERY SYSTEM
GB201018750D0 (en) Drug delivery system
GB201121693D0 (en) Medicament delivery technology